SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 17, 2006--Hana Biosciences (NASDAQ:HNAB): -- Trial Represents First Stage of Registration Program for Targeted Chemotherapy Agent -- Multinational, Multicenter Phase III Randomized Trial in ALL to Commence before Year-End 2006 Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced the initiation of a multi-center Phase II clinical trial of Marqibo(R) (vincristine sulfate liposomes injection) in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). This study is designed to support a Phase III pivotal clinical trial of Marqibo for the treatment of ALL.
